BRIEF published on 07/24/2024 at 12:35, 3 months 27 days ago Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Merger Financing Nasdaq Biopharmaceutical QTORIN™
BRIEF published on 07/24/2024 at 12:35, 3 months 27 days ago Palvella Therapeutics et Pieris Pharmaceuticals annoncent un accord de fusion définitif Financement Nasdaq Biopharmaceutique Fusionnement QTORIN™
PRESS RELEASE published on 07/24/2024 at 12:30, 3 months 27 days ago Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Palvella Therapeutics, Inc. and Pieris Pharmaceuticals, Inc. announce a merger to focus on rare genetic skin diseases with QTORIN™ rapamycin. Joint webcast on July 24 at 8:30am ET Merger Clinical-stage Genetic Skin Diseases QTORIN™ Rapamycin FDA-approved Therapies
BRIEF published on 04/19/2024 at 18:15, 7 months 1 day ago Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split Reverse Stock Split Nasdaq Compliance Financial Regulation Pieris Pharmaceuticals Stock Adjustment
BRIEF published on 04/19/2024 at 18:15, 7 months 1 day ago Pieris Pharmaceuticals annonce un regroupement d'actions de 1 pour 80 Réglementation Financière Pieris Pharmaceutique Regroupement D'actions Inversé Conformité NASDAQ Ajustement Des Stocks
PRESS RELEASE published on 04/19/2024 at 18:10, 7 months 1 day ago Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split Pieris Pharmaceuticals, Inc. announces a 1-for-80 reverse stock split effective on April 22, 2024, to comply with Nasdaq listing requirements. No fractional shares will be issued Reverse Stock Split Compliance Nasdaq Pieris Pharmaceuticals Stockholder Ownership
BRIEF published on 03/27/2024 at 13:05, 7 months 24 days ago Pieris Pharmaceuticals Announces New Strategy to Maximize Financial Potential Shareholder Value Pieris Pharmaceuticals Strategic Reorganization Milestone Payments Royalty Potential
BRIEF published on 03/27/2024 at 13:05, 7 months 24 days ago Pieris Pharmaceuticals annonce une nouvelle stratégie pour maximiser le potentiel financier Valeur Pour Les Actionnaires Pieris Pharmaceutique Réorganisation Stratégique Paiements D'étape Potentiel De Redevances
PRESS RELEASE published on 03/27/2024 at 13:00, 7 months 24 days ago Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential Pieris Pharmaceuticals, Inc. announces strategic repositioning to maximize milestone and royalty potential from immuno-oncology assets. Cost-saving measures extend cash runway into 2027 Strategic Repositioning Cost-saving Measures Pieris Pharmaceuticals Milestone Payments Immuno-oncology Assets
Published on 11/21/2024 at 09:00, 29 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 8 hours 54 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 4 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 29 minutes ago Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 29 minutes ago Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates
Published on 11/21/2024 at 08:59, 29 minutes ago Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 29 minutes ago Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 14 minutes ago EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.
Published on 11/21/2024 at 08:09, 1 hour 19 minutes ago KAP HOLDS ITS GROUND IN A DIFFICULT INDUSTRY ENVIRONMENT IN THE FIRST NINE MONTHS OF 2024
Published on 11/21/2024 at 06:58, 2 hours 31 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 31 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 31 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 21 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 9 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
